Financials Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Delayed Nasdaq 15:57:03 2024-06-17 EDT 5-day change 1st Jan Change
32.32 USD -3.20% Intraday chart for Protagonist Therapeutics, Inc. -2.25% +41.41%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 191.8 867.3 1,632 536.8 1,323 1,958 - -
Enterprise Value (EV) 1 68.58 561.4 1,305 411 1,136 1,387 1,263 1,958
P/E ratio -2.37 x -10.5 x -12.6 x -4.2 x -16.5 x 21.9 x -24.4 x -33.9 x
Yield - - - - - - - -
Capitalization / Revenue 830 x 30.3 x 59.7 x 20.2 x 22 x 6.71 x 20.9 x 13.4 x
EV / Revenue 297 x 19.6 x 47.7 x 15.5 x 18.9 x 4.75 x 13.5 x 13.4 x
EV / EBITDA - -8.81 x -10.4 x - -12.3 x 6.54 x -20.7 x -
EV / FCF -1.62 x -7.7 x -12 x -3.77 x -16 x 7.06 x -11.2 x -18.1 x
FCF Yield -61.8% -13% -8.35% -26.5% -6.24% 14.2% -8.95% -5.51%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 27,206 43,019 47,728 49,198 57,678 58,652 - -
Reference price 2 7.050 20.16 34.20 10.91 22.93 33.39 33.39 33.39
Announcement Date 20-03-10 21-03-10 22-02-28 23-03-15 24-02-27 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.231 28.63 27.36 26.58 60 291.7 93.78 145.6
EBITDA 1 - -63.73 -125 - -92.68 212 -61 -
EBIT 1 -80.52 -64.52 -125.8 -131.4 -93.65 101.8 -56.97 -59.27
Operating Margin -34,857.58% -225.36% -460.01% -494.24% -156.09% 34.9% -60.75% -40.71%
Earnings before Tax (EBT) 1 -77.88 -64.84 -125.6 -127.4 -78.96 138.7 -31.32 -47.31
Net income 1 -77.19 -66.15 -125.6 -127.4 -78.96 103.3 -34.36 -50.55
Net margin -33,414.29% -231.07% -458.94% -479.26% -131.59% 35.41% -36.64% -34.72%
EPS 2 -2.980 -1.920 -2.710 -2.600 -1.390 1.523 -1.371 -0.9850
Free Cash Flow 1 -42.4 -72.96 -109 -108.9 -70.84 196.5 -113 -108
FCF margin -18,355.41% -254.84% -398.31% -409.81% -118.08% 67.37% -120.49% -74.17%
FCF Conversion (EBITDA) - - - - - 92.69% - -
FCF Conversion (Net income) - - - - - 190.28% - -
Dividend per Share - - - - - - - -
Announcement Date 20-03-10 21-03-10 22-02-28 23-03-15 24-02-27 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 8.617 25.72 0.859 - - - - - 60 255 6.667 0.8333 29.17 - 100
EBITDA 1 -36.78 -20.86 -41.18 -32.03 -36.26 -35.77 -42.12 -38.08 23.3 206.5 -44 -45 94 - -
EBIT 1 -37.02 -21.11 -41.44 -32.3 -36.52 -36.02 -42.35 -38.33 23.05 206.3 -39.76 -46.15 -18.61 - -
Operating Margin -429.57% -82.07% -4,824.56% - - - - - 38.42% 80.92% -596.47% -5,537.84% -63.8% - -
Earnings before Tax (EBT) 1 -36.91 -20.93 -41.04 -31.23 -34.19 -33.72 -38.46 -34.1 27.34 210.7 -42.86 -43.3 14.16 - -
Net income 1 -36.91 -20.93 -41.04 -31.23 -34.19 -33.72 -38.46 -34.1 27.34 207.3 -44.8 -44.96 -10.97 - -
Net margin -428.3% -81.37% -4,777.3% - - - - - 45.56% 81.32% -671.95% -5,395.51% -37.6% - -
EPS 2 -0.7700 -0.4300 -0.8400 -0.6400 -0.6900 -0.6700 -0.6800 -0.5800 0.4400 3.260 -0.7324 -0.7350 -0.2213 -0.7650 0.6200
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 22-02-28 22-05-04 22-08-04 22-11-08 23-03-15 23-05-04 23-08-03 23-11-02 24-02-27 24-05-07 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 123 306 327 126 187 572 695 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -42.4 -73 -109 -109 -70.8 197 -113 -108
ROE (net income / shareholders' equity) - -36.8% -43.3% -49.4% -28.6% 48.7% -6.57% -
ROA (Net income/ Total Assets) - -27.6% -37.4% -42.8% -26.1% 44.6% -6.11% -
Assets 1 - 239.7 336.1 297.8 302.9 231.4 562.7 -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.97 0.47 1.1 0.8 0.61 - - -
Capex / Sales 418.61% 1.65% 4.02% 2.99% 1.02% - - -
Announcement Date 20-03-10 21-03-10 22-02-28 23-03-15 24-02-27 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
33.39 USD
Average target price
43.83 USD
Spread / Average Target
+31.28%
Consensus
  1. Stock Market
  2. Equities
  3. PTGX Stock
  4. Financials Protagonist Therapeutics, Inc.